-
1
-
-
60749109846
-
Cell cycle, CDKs and cancer: A changing paradigm
-
Malumbres M and Barbacid M (2009). Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9, 153–166.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 153-166
-
-
Malumbres, M.1
Barbacid, M.2
-
2
-
-
84883183501
-
Phospho-Ser/Thr-binding domains: Navigating the cell cycle and DNA damage response
-
[2] Reinhardt HC and Yaffe MB (2013). Phospho-Ser/Thr-binding domains: navigating the cell cycle and DNA damage response. Nat Rev Mol Cell Biol 14, 563–580.
-
(2013)
Nat Rev Mol Cell Biol
, vol.14
, pp. 563-580
-
-
Reinhardt, H.C.1
Yaffe, M.B.2
-
3
-
-
77955167321
-
Multifaceted polo-like kinases: Drug targets and antitargets for cancer therapy
-
[3] Strebhardt K (2010). Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9, 643–660.
-
(2010)
Nat Rev Drug Discov
, vol.9
, pp. 643-660
-
-
Strebhardt, K.1
-
4
-
-
0023804548
-
Polo, a mitotic mutant of Drosophila displaying abnormal spindle poles
-
[4] Sunkel CE and Glover DM (1988). Polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J Cell Sci 89, 25–38.
-
(1988)
J Cell Sci
, vol.89
, pp. 25-38
-
-
Sunkel, C.E.1
Glover, D.M.2
-
5
-
-
33645316142
-
Targeting polo-like kinase 1 for cancer therapy
-
[5] Strebhardt K and Ullrich A (2006). Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6, 321–330.
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 321-330
-
-
Strebhardt, K.1
Ullrich, A.2
-
6
-
-
0037200029
-
A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells
-
[6] Seong YS, Kamijo K, Lee JS, Fernandez E, Kuriyama R, Miki T, and Lee KS (2002). A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. J Biol Chem 277, 32282–32293.
-
(2002)
J Biol Chem
, vol.277
, pp. 32282-32293
-
-
Seong, Y.S.1
Kamijo, K.2
Lee, J.S.3
Fernandez, E.4
Kuriyama, R.5
Miki, T.6
Lee, K.S.7
-
7
-
-
79952263859
-
Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression
-
[7] de Cárcer G, Escobar B, Higuero AM, García L, Ansón A, Pérez G, Mollejo M, Manning G, Melendez B, and Abad-Rodríguez J, et al (2011). Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression. Mol Cell Biol 31, 1225–1239.
-
(2011)
Mol Cell Biol
, vol.31
, pp. 1225-1239
-
-
De Cárcer, G.1
Escobar, B.2
Higuero, A.M.3
García, L.4
Ansón, A.5
Pérez, G.6
Mollejo, M.7
Manning, G.8
Melendez, B.9
Abad-Rodríguez, J.10
-
8
-
-
55849147330
-
Polo-like kinase 1 is essential for early embryonic development and tumor suppression
-
[8] Lu LY, Wood JL, Minter-Dykhouse K, Ye L, Saunders TL, Yu X, and Chen J (2008). Polo-like kinase 1 is essential for early embryonic development and tumor suppression. Mol Cell Biol 28, 6870–6876.
-
(2008)
Mol Cell Biol
, vol.28
, pp. 6870-6876
-
-
Lu, L.Y.1
Wood, J.L.2
Minter-Dykhouse, K.3
Ye, L.4
Saunders, T.L.5
Yu, X.6
Chen, J.7
-
9
-
-
0030462914
-
Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes
-
[9] Lane HA and Nigg EA (1996). Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 135, 1701–1713.
-
(1996)
J Cell Biol
, vol.135
, pp. 1701-1713
-
-
Lane, H.A.1
Nigg, E.A.2
-
10
-
-
27944453949
-
Phosphorylation of Nlp by Plk1 negatively regulates its dynein-dynactin-dependent targeting to the centrosome
-
[10] Casenghi M, Barr FA, and Nigg EA (2005). Phosphorylation of Nlp by Plk1 negatively regulates its dynein-dynactin-dependent targeting to the centrosome. J Cell Sci 118, 5101–5108.
-
(2005)
J Cell Sci
, vol.118
, pp. 5101-5108
-
-
Casenghi, M.1
Barr, F.A.2
Nigg, E.A.3
-
11
-
-
32244446180
-
A functional interplay between Aurora-A, Plk1 and TPX2 at spindle poles: Plk1 controls centrosomal localization of Aurora-A and TPX2 spindle association
-
[11] De Luca M, Lavia P, and Guarguaglini G (2006). A functional interplay between Aurora-A, Plk1 and TPX2 at spindle poles: Plk1 controls centrosomal localization of Aurora-A and TPX2 spindle association. Cell Cycle 5, 296–303.
-
(2006)
Cell Cycle
, vol.5
, pp. 296-303
-
-
De Luca, M.1
Lavia, P.2
Guarguaglini, G.3
-
12
-
-
0034048515
-
Imburgia C,FornwaldJ, ScottG,and MarshallLA(2000). The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase
-
[12] Roshak AK, Capper EA, Imburgia C,FornwaldJ, ScottG,and MarshallLA(2000). The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell Signal 12, 405–411.
-
Cell Signal
, vol.12
, pp. 405-411
-
-
Roshak, A.K.1
Capper, E.A.2
-
13
-
-
4444321565
-
Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells
-
[13] van Vugt MA, Brás A, and Medema RH (2004). Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol Cell 15, 799–811.
-
(2004)
Mol Cell
, vol.15
, pp. 799-811
-
-
Van Vugt, M.A.1
Brás, A.2
Medema, R.H.3
-
14
-
-
77957041423
-
Polo-like kinase 1 phosphorylation of p150Glued facilitates nuclear envelope breakdown during prophase
-
[14] Li H, Liu XS, Yang X, Song B, Wang Y, and Liu X (2010). Polo-like kinase 1 phosphorylation of p150Glued facilitates nuclear envelope breakdown during prophase. Proc Natl Acad Sci U S A 107, 14633–14638.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 14633-14638
-
-
Li, H.1
Liu, X.S.2
Yang, X.3
Song, B.4
Wang, Y.5
Liu, X.6
-
15
-
-
0036209010
-
The dissociation of cohesin from chromosomes in prophase is regulated by Polo-like kinase
-
[15] Sumara I, Vorlaufer E, Stukenberg PT, Kelm O, Redemann N, Nigg EA, and Peters JM (2002). The dissociation of cohesin from chromosomes in prophase is regulated by Polo-like kinase. Mol Cell 9, 515–525.
-
(2002)
Mol Cell
, vol.9
, pp. 515-525
-
-
Sumara, I.1
Vorlaufer, E.2
Stukenberg, P.T.3
Kelm, O.4
Redemann, N.5
Nigg, E.A.6
Peters, J.M.7
-
16
-
-
33751070826
-
Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation
-
[16] Kang YH, Park JE, Yu LR, Soung NK, Yun SM, Bang JK, Seong YS, Yu H, Garfield S, and Veenstra TD, et al (2006). Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation. Mol Cell 24, 409–422.
-
(2006)
Mol Cell
, vol.24
, pp. 409-422
-
-
Kang, Y.H.1
Park, J.E.2
Yu, L.R.3
Soung, N.K.4
Yun, S.M.5
Bang, J.K.6
Seong, Y.S.7
Yu, H.8
Garfield, S.9
Veenstra, T.D.10
-
17
-
-
77956394930
-
Phosphorylation of CLIP-170 by Plk1 and CK2 promotes timely formation of kinetochore-microtubule attachments
-
[17] Li H, Liu XS, Yang X, Wang Y, Wang Y, Turner JR, and Liu X (2010). Phosphorylation of CLIP-170 by Plk1 and CK2 promotes timely formation of kinetochore-microtubule attachments. EMBO J 29, 2953–2965.
-
(2010)
EMBO J
, vol.29
, pp. 2953-2965
-
-
Li, H.1
Liu, X.S.2
Yang, X.3
Wang, Y.4
Wang, Y.5
Turner, J.R.6
Liu, X.7
-
18
-
-
84868695288
-
Plk1 phosphorylates Sgt1 at the kinetochores to promote timely kinetochore-microtubule attachment
-
[18] Liu XS, Song B, Tang J, Liu W, Kuang S, and Liu X (2012). Plk1 phosphorylates Sgt1 at the kinetochores to promote timely kinetochore-microtubule attachment. Mol Cell Biol 32, 4053–4067.
-
(2012)
Mol Cell Biol
, vol.32
, pp. 4053-4067
-
-
Liu, X.S.1
Song, B.2
Tang, J.3
Liu, W.4
Kuang, S.5
Liu, X.6
-
19
-
-
0037013326
-
The cyclin-ubiquitin ligase activity of cyclosome/APC is jointly activated by protein kinases Cdk1-cyclin B and Plk
-
[19] Golan A, Yudkovsky Y, and Hershko A (2002). The cyclin-ubiquitin ligase activity of cyclosome/APC is jointly activated by protein kinases Cdk1-cyclin B and Plk. J Biol Chem 277, 15552–15557.
-
(2002)
J Biol Chem
, vol.277
, pp. 15552-15557
-
-
Golan, A.1
Yudkovsky, Y.2
Hershko, A.3
-
20
-
-
9444235650
-
Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbe-taTrCP-dependent destruction of the APC inhibitor Emi1
-
[20] Hansen DV, Loktev AV, Ban KH, and Jackson PK (2004). Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbe-taTrCP-dependent destruction of the APC inhibitor Emi1. Mol Biol Cell 15, 5623–5634.
-
(2004)
Mol Biol Cell
, vol.15
, pp. 5623-5634
-
-
Hansen, D.V.1
Loktev, A.V.2
Ban, K.H.3
Jackson, P.K.4
-
21
-
-
34047119210
-
Choice of Plk1 docking partners during mitosis and cytokinesis is controlled by the activation state of Cdk1
-
[21] Neef R, Gruneberg U, Kopajtich R, Li X, Nigg EA, Sillje H, and Barr FA (2007). Choice of Plk1 docking partners during mitosis and cytokinesis is controlled by the activation state of Cdk1. Nat Cell Biol 9, 436–444.
-
(2007)
Nat Cell Biol
, vol.9
, pp. 436-444
-
-
Neef, R.1
Gruneberg, U.2
Kopajtich, R.3
Li, X.4
Nigg, E.A.5
Sillje, H.6
Barr, F.A.7
-
22
-
-
66249092744
-
Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF complex to initiate cleavage furrow formation
-
[22] Wolfe BA, Takaki T, Petronczki M, and Glotzer M (2009). Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF complex to initiate cleavage furrow formation. PLoS Biol 7, e1000110.
-
(2009)
Plos Biol
, pp. 7
-
-
Wolfe, B.A.1
Takaki, T.2
Petronczki, M.3
Glotzer, M.4
-
23
-
-
62849123093
-
Polo-like kinases: Conservation and divergence in their functions and regulation
-
[23] Archambault V and Glover DM (2009). Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol 10, 265–275.
-
(2009)
Nat Rev Mol Cell Biol
, vol.10
, pp. 265-275
-
-
Archambault, V.1
Glover, D.M.2
-
24
-
-
51349144633
-
Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery
-
[24] Macurek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R, Clouin C, Taylor SS, Yaffe MB, and Medema RH (2008). Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 455, 119–123.
-
(2008)
Nature
, vol.455
, pp. 119-123
-
-
Macurek, L.1
Lindqvist, A.2
Lim, D.3
Lampson, M.A.4
Klompmaker, R.5
Freire, R.6
Clouin, C.7
Taylor, S.S.8
Yaffe, M.B.9
Medema, R.H.10
-
25
-
-
1642458099
-
Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells
-
[25] Lindon C and Pines J (2004). Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells. J Cell Biol 164, 233–241.
-
(2004)
J Cell Biol
, vol.164
, pp. 233-241
-
-
Lindon, C.1
Pines, J.2
-
26
-
-
56449109605
-
Plk2 regulated centriole duplication is dependent on its localization to the centrioles and a functional polo-box domain
-
[26] Cizmecioglu O, Warnke S, Arnold M, Duensing S, and Hoffmann I (2008). Plk2 regulated centriole duplication is dependent on its localization to the centrioles and a functional polo-box domain. Cell Cycle 7, 3548–3555.
-
(2008)
Cell Cycle
, vol.7
, pp. 3548-3555
-
-
Cizmecioglu, O.1
Warnke, S.2
Arnold, M.3
Duensing, S.4
Hoffmann, I.5
-
27
-
-
0042132030
-
Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells
-
[27] Burns TF, Fei P, Scata KA, Dicker DT, and El-Deiry WS (2003). Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol 23, 5556–5571.
-
(2003)
Mol Cell Biol
, vol.23
, pp. 5556-5571
-
-
Burns, T.F.1
Fei, P.2
Scata, K.A.3
Dicker, D.T.4
El-Deiry, W.S.5
-
28
-
-
0141781074
-
Role of Plk2 (Snk) in mouse development and cell proliferation
-
[28] Ma S, Charron J, and Erikson RL (2003). Role of Plk2 (Snk) in mouse development and cell proliferation. Mol Cell Biol 23, 6936–6943.
-
(2003)
Mol Cell Biol
, vol.23
, pp. 6936-6943
-
-
Ma, S.1
Charron, J.2
Erikson, R.L.3
-
29
-
-
49249127687
-
Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions
-
[29] Yang Y, Bai J, Shen R, Brown SA, Komissarova E, Huang Y, Jiang N, Alberts GF, Costa M, and Lu L, et al (2008). Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. Cancer Res 68, 4077–4085.
-
(2008)
Cancer Res
, vol.68
, pp. 4077-4085
-
-
Yang, Y.1
Bai, J.2
Shen, R.3
Brown, S.A.4
Komissarova, E.5
Huang, Y.6
Jiang, N.7
Alberts, G.F.8
Costa, M.9
Lu, L.10
-
30
-
-
33846904706
-
Polo-like kinase 3 is required for entry into S phase
-
[30] Zimmerman WC and Erikson RL (2007). Polo-like kinase 3 is required for entry into S phase. Proc Natl Acad Sci U S A 104, 1847–1852.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 1847-1852
-
-
Zimmerman, W.C.1
Erikson, R.L.2
-
31
-
-
33744520878
-
Polo box domain of Plk3 functions as a centrosome localization signal, overexpression of which causes mitotic arrest, cytokinesis defects, and apoptosis
-
[31] Jiang N, Wang X, Jhanwar-Uniyal M, Darzynkiewicz Z, and Dai W (2006). Polo box domain of Plk3 functions as a centrosome localization signal, overexpression of which causes mitotic arrest, cytokinesis defects, and apoptosis. J Biol Chem 281, 10577–10582.
-
(2006)
J Biol Chem
, vol.281
, pp. 10577-10582
-
-
Jiang, N.1
Wang, X.2
Jhanwar-Uniyal, M.3
Darzynkiewicz, Z.4
Dai, W.5
-
32
-
-
0035916794
-
Late mitotic failure in mice lacking Sak, a polo-like kinase
-
[32] Hudson JW, Kozarova A, Cheung P, Macmillan JC, Swallow CJ, Cross JC, and Dennis JW (2001). Late mitotic failure in mice lacking Sak, a polo-like kinase. Curr Biol 11, 441–446.
-
(2001)
Curr Biol
, vol.11
, pp. 441-446
-
-
Hudson, J.W.1
Kozarova, A.2
Cheung, P.3
Macmillan, J.C.4
Swallow, C.J.5
Cross, J.C.6
Dennis, J.W.7
-
33
-
-
0029743890
-
Constitutive expression of murine Sak-a suppresses cell growth and induces multinucleation
-
[33] Fode C, Binkert C, and Dennis JW (1996). Constitutive expression of murine Sak-a suppresses cell growth and induces multinucleation. Mol Cell Biol 16, 4665–4672.
-
(1996)
Mol Cell Biol
, vol.16
, pp. 4665-4672
-
-
Fode, C.1
Binkert, C.2
Dennis, J.W.3
-
34
-
-
77953242760
-
The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus
-
[34] Andrysik Z, Bernstein WZ, Deng L, Myer DL, Li YQ, Tischfield JA, Stambrook PJ, and Bahassi EM (2010). The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus. Nucleic Acids Res 38, 2931–2943.
-
(2010)
Nucleic Acids Res
, vol.38
, pp. 2931-2943
-
-
Rysik, Z.1
Bernstein, W.Z.2
Deng, L.3
Myer, D.L.4
Li, Y.Q.5
Tischfield, J.A.6
Stambrook, P.J.7
Bahassi, E.M.8
-
35
-
-
84890278751
-
The role of polo-like kinase 1 in carcinogenesis: Cause or consequence?
-
[35] Cholewa BD, Liu X, and Ahmad N (2013). The role of polo-like kinase 1 in carcinogenesis: cause or consequence? Cancer Res 73, 6848–6855.
-
(2013)
Cancer Res
, vol.73
, pp. 6848-6855
-
-
Cholewa, B.D.1
Liu, X.2
Ahmad, N.3
-
36
-
-
30144435660
-
Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies
-
[36] Syed N, Smith P, Sullivan A, Spender LC, Dyer M, Karran L, O'Nions J, Allday M, Hoffmann I, and Crawford D, et al (2006). Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 107, 250–256.
-
(2006)
Blood
, vol.107
, pp. 250-256
-
-
Syed, N.1
Smith, P.2
Sullivan, A.3
Spender, L.C.4
Dyer, M.5
Karran, L.6
O'nions, J.7
Allday, M.8
Hoffmann, I.9
Crawford, D.10
-
37
-
-
84863215537
-
Polo like kinase 2 tumour suppressor and cancer biomarker: New perspectives on drug sensitivity/resistance in ovarian cancer
-
[37] Coley HM, Hatzimichael E, Blagden S, McNeish I, Thompson A, Crook T, and Syed N (2012). Polo like kinase 2 tumour suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer. Oncotarget 3, 78–83.
-
(2012)
Oncotarget
, vol.3
, pp. 78-83
-
-
Coley, H.M.1
Hatzimichael, E.2
Blagden, S.3
McNeish, I.4
Thompson, A.5
Crook, T.6
Syed, N.7
-
38
-
-
55749099505
-
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations
-
[38] Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT, Chen P, Wang Y, Yan M, and Qian Z, et al (2008). Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 105, 15535–15540.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 15535-15540
-
-
Li, Z.1
Lu, J.2
Sun, M.3
Mi, S.4
Zhang, H.5
Luo, R.T.6
Chen, P.7
Wang, Y.8
Yan, M.9
Qian, Z.10
-
39
-
-
0029770725
-
Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas
-
[39] Li B, Ouyang B, Pan H, Reissmann PT, Slamon DJ, Arceci R, Lu L, and Dai W (1996). Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas. J Biol Chem 271, 19402–19408.
-
(1996)
J Biol Chem
, vol.271
, pp. 19402-19408
-
-
Li, B.1
Ouyang, B.2
Pan, H.3
Reissmann, P.T.4
Slamon, D.J.5
Arceci, R.6
Lu, L.7
Dai, W.8
-
40
-
-
17144458001
-
PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer
-
[40] Dai W, Li Y, Ouyang B, Pan H, Reissmann P, Li J, Wiest J, Stambrook P, Gluckman JL, and Noffsinger A, et al (2000). PRK, a cell cycle gene localized to 8p21, is downregulated in head and neck cancer. Genes Chromosomes Cancer 27, 332–336.
-
(2000)
Genes Chromosomes Cancer
, vol.27
, pp. 332-336
-
-
Dai, W.1
Li, Y.2
Ouyang, B.3
Pan, H.4
Reissmann, P.5
Li, J.6
Wiest, J.7
Stambrook, P.8
Gluckman, J.L.9
Noffsinger, A.10
-
41
-
-
0034785447
-
Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer
-
[41] Macmillan JC, Hudson JW, Bull S, Dennis JW, and Swallow CJ (2001). Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer. Ann Surg Oncol 8, 729–740.
-
(2001)
Ann Surg Oncol
, vol.8
, pp. 729-740
-
-
Macmillan, J.C.1
Hudson, J.W.2
Bull, S.3
Dennis, J.W.4
Swallow, C.J.5
-
42
-
-
85029013822
-
Inhibition of Polo-like kinase 4 as an anti-cancer strategy
-
Abstract LB-215
-
[42] Mason J, Wei S, Luo X, Nadeem V, Kiarash R, Huang P, Awrey D, Leung G, Beletskaya I, and Feher M, et al (2011). Inhibition of Polo-like kinase 4 as an anti-cancer strategy. Cancer Res 71 [Abstract LB-215].
-
(2011)
Cancer Res
, pp. 71
-
-
Mason, J.1
Wei, S.2
Luo, X.3
Nadeem, V.4
Kiarash, R.5
Huang, P.6
Awrey, D.7
Leung, G.8
Beletskaya, I.9
Feher, M.10
-
43
-
-
66149091940
-
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene
-
[43] Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, and Elledge SJ (2009). A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835–848.
-
(2009)
Cell
, vol.137
, pp. 835-848
-
-
Luo, J.1
Emanuele, M.J.2
Li, D.3
Creighton, C.J.4
Schlabach, M.R.5
Westbrook, T.F.6
Wong, K.K.7
Elledge, S.J.8
-
44
-
-
62649112876
-
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
-
[44] Sur S, Pagliarini R, Bunz F, Rago C, Diaz Jr LA, Kinzler KW, Vogelstein B, and Papadopoulos N (2009). A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A 106, 3964–3969.
-
(2009)
Proc Natl Acad Sci U S A
, vol.106
, pp. 3964-3969
-
-
Sur, S.1
Pagliarini, R.2
Bunz, F.3
Rago, C.4
Diaz, L.A.5
Kinzler, K.W.6
Vogelstein, B.7
Papadopoulos, N.8
-
45
-
-
67650529837
-
Plk1-mediated phosphorylation of Topors regulates p53 stability
-
[45] Yang X, Li H, Zhou Z, Wang WH, Deng A, Andrisani O, and Liu X (2009). Plk1-mediated phosphorylation of Topors regulates p53 stability. J Biol Chem 284, 18588–18592.
-
(2009)
J Biol Chem
, vol.284
, pp. 18588-18592
-
-
Yang, X.1
Li, H.2
Zhou, Z.3
Wang, W.H.4
Deng, A.5
Risani, O.6
Liu, X.7
-
46
-
-
77955058029
-
Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery
-
[46] Liu XS, Li H, Song B, and Liu X (2010). Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery. EMBO Rep 11, 626–632.
-
(2010)
EMBO Rep
, vol.11
, pp. 626-632
-
-
Liu, X.S.1
Li, H.2
Song, B.3
Liu, X.4
-
47
-
-
0038624074
-
Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells
-
[47] Liu X and Erikson RL (2003). Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 100, 5789–5794.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 5789-5794
-
-
Liu, X.1
Erikson, R.L.2
-
48
-
-
33644767315
-
Normal cells, but not cancer cells, survive severe Plk1 depletion
-
[48] Liu X, Lei M, and Erikson RL (2006). Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 26, 2093–2108.
-
(2006)
Mol Cell Biol
, vol.26
, pp. 2093-2108
-
-
Liu, X.1
Lei, M.2
Erikson, R.L.3
-
49
-
-
16844369144
-
Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals
-
[49] Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, and Luo Y (2005). Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res 65, 2698–2704.
-
(2005)
Cancer Res
, vol.65
, pp. 2698-2704
-
-
Guan, R.1
Tapang, P.2
Leverson, J.D.3
Albert, D.4
Giranda, V.L.5
Luo, Y.6
-
50
-
-
84899562295
-
P53-Dependent and cell specific epigenetic regulation of the polo-like kinases under oxidative stress
-
[50] Ward A and Hudson JW (2014). p53-Dependent and cell specific epigenetic regulation of the polo-like kinases under oxidative stress. PLoS One 9, e87918.
-
(2014)
Plos One
, vol.9
-
-
Ward, A.1
Hudson, J.W.2
-
51
-
-
0035900745
-
Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway
-
[51] Xie S, Wu H, Wang Q, Cogswell JP, Husain I, Conn C, Stambrook P, Jhanwar-Uniyal M, and Dai W (2001). Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway. J Biol Chem 276, 43305–43312.
-
(2001)
J Biol Chem
, vol.276
, pp. 43305-43312
-
-
Xie, S.1
Wu, H.2
Wang, Q.3
Cogswell, J.P.4
Husain, I.5
Conn, C.6
Stambrook, P.7
Jhanwar-Uniyal, M.8
Dai, W.9
-
52
-
-
2942544699
-
Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1
-
[52] Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, and Strebhardt K (2004). Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 96, 862–872.
-
(2004)
J Natl Cancer Inst
, vol.96
, pp. 862-872
-
-
Spankuch, B.1
Matthess, Y.2
Knecht, R.3
Zimmer, B.4
Kaufmann, M.5
Strebhardt, K.6
-
53
-
-
80053893481
-
Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation
-
[53] Liu XS, Song B, Elzey BD, Ratliff TL, Konieczny SF, Cheng L, Ahmad N, and Liu X (2011). Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. J Biol Chem 286, 35795–35800.
-
(2011)
J Biol Chem
, vol.286
, pp. 35795-35800
-
-
Liu, X.S.1
Song, B.2
Elzey, B.D.3
Ratliff, T.L.4
Konieczny, S.F.5
Cheng, L.6
Ahmad, N.7
Liu, X.8
-
54
-
-
79955068894
-
Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo
-
[54] Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, Hornicek FJ, and Duan Z (2011). Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. Anticancer Drugs 22, 444–453.
-
(2011)
Anticancer Drugs
, vol.22
, pp. 444-453
-
-
Liu, X.1
Choy, E.2
Harmon, D.3
Yang, S.4
Yang, C.5
Mankin, H.6
Hornicek, F.J.7
Duan, Z.8
-
55
-
-
23044488055
-
Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis
-
[55] Ko MA, Rosario CO, Hudson JW, Kulkarni S, Pollett A, Dennis JW, and Swallow CJ (2005). Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet 37, 883–888.
-
(2005)
Nat Genet
, vol.37
, pp. 883-888
-
-
Ko, M.A.1
Rosario, C.O.2
Hudson, J.W.3
Kulkarni, S.4
Pollett, A.5
Dennis, J.W.6
Swallow, C.J.7
-
56
-
-
17644368237
-
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
-
[56] Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, Jiang J, Holland J, and Reddy EP (2005). ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7, 275–286.
-
(2005)
Cancer Cell
, vol.7
, pp. 275-286
-
-
Gumireddy, K.1
Reddy, M.V.2
Cosenza, S.C.3
Boominathan, R.4
Baker, S.J.5
Papathi, N.6
Jiang, J.7
Holland, J.8
Reddy, E.P.9
-
57
-
-
65649105075
-
BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity
-
[57] Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, Haslinger C, Garin-Chesa P, and Adolf GR (2009). BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 15, 3094–3102.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3094-3102
-
-
Rudolph, D.1
Steegmaier, M.2
Hoffmann, M.3
Grauert, M.4
Baum, A.5
Quant, J.6
Haslinger, C.7
Garin-Chesa, P.8
Adolf, G.R.9
-
58
-
-
70149099357
-
Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis
-
[58] Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, and Courtney MP, et al (2009). Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 69, 6969–6977.
-
(2009)
Cancer Res
, vol.69
, pp. 6969-6977
-
-
Gilmartin, A.G.1
Bleam, M.R.2
Richter, M.C.3
Erskine, S.G.4
Kruger, R.G.5
Madden, L.6
Hassler, D.F.7
Smith, G.K.8
Gontarek, R.R.9
Courtney, M.P.10
-
59
-
-
33847403132
-
In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1
-
[59] Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, Noro N, Furuta M, Emmitte KA, and Gilmer TM, et al (2007). In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther 6, 450–459.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 450-459
-
-
Lansing, T.J.1
McConnell, R.T.2
Duckett, D.R.3
Spehar, G.M.4
Knick, V.B.5
Hassler, D.F.6
Noro, N.7
Furuta, M.8
Emmitte, K.A.9
Gilmer, T.M.10
-
60
-
-
68249137199
-
Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1
-
[60] Yun SM, Moulaei T, Lim D, Bang JK, Park JE, Shenoy SR, Liu F, Kang YH, Liao C, and Soung NK, et al (2009). Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol 16, 876–882.
-
(2009)
Nat Struct Mol Biol
, vol.16
, pp. 876-882
-
-
Yun, S.M.1
Moulaei, T.2
Lim, D.3
Bang, J.K.4
Park, J.E.5
Shenoy, S.R.6
Liu, F.7
Kang, Y.H.8
Liao, C.9
Soung, N.K.10
-
61
-
-
59049093510
-
Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition
-
[61] Watanabe N, Sekine T, Takagi M, Iwasaki J, Imamoto N, Kawasaki H, and Osada H (2009). Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J Biol Chem 284, 2344–2353.
-
(2009)
J Biol Chem
, vol.284
, pp. 2344-2353
-
-
Watanabe, N.1
Sekine, T.2
Takagi, M.3
Iwasaki, J.4
Imamoto, N.5
Kawasaki, H.6
Osada, H.7
-
62
-
-
43149093993
-
Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions
-
[62] Reindl W, Yuan J, Kramer A, Strebhardt K, and Berg T (2008). Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol 15, 459–466.
-
(2008)
Chem Biol
, vol.15
, pp. 459-466
-
-
Reindl, W.1
Yuan, J.2
Kramer, A.3
Strebhardt, K.4
Berg, T.5
-
64
-
-
85019300367
-
-
[64] Reddy EP (2014). Deciphering the novel mechanism of rigosertib. Webcast http://globenewswire.com/news-release/2014/01/17/603196/10064629/en/Onconova-Therapeutics-Inc-to-Host-Webcast-Regarding-Insights-Into-Rigosertib-Mechanism-of-Action-With-Scientific-Founder-Dr-E-Premkumar-Reddy.html; 2014.
-
(2014)
Deciphering the Novel Mechanism of Rigosertib
-
-
Reddy, E.P.1
-
65
-
-
84893249799
-
PI3K and cancer: Lessons, challenges and opportunities
-
[65] Fruman DA and Rommel C (2014). PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13, 140–156.
-
(2014)
Nat Rev Drug Discov
, vol.13
, pp. 140-156
-
-
Fruman, D.A.1
Rommel, C.2
-
66
-
-
84920698054
-
Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
-
[66] Gjertsen BT and Schöffski P (2015). Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia 29, 11–19.
-
(2015)
Leukemia
, vol.29
, pp. 11-19
-
-
Gjertsen, B.T.1
Schöffski, P.2
-
67
-
-
84900540918
-
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous Polo-like kinase inhibitor, in patients with advanced solid malignancies
-
[67] Lin C-C, Su W, Yen C-J, Hsu C-H, Su W-P, Yeh K-H, Lu Y-S, Cheng AL, Huang DC, and Fritsch H, et al (2014). A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous Polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer 110, 2434–2440.
-
(2014)
Br J Cancer
, vol.110
, pp. 2434-2440
-
-
Lin, C.-C.1
Su, W.2
Yen, C.-J.3
Hsu, C.-H.4
Su, W.-P.5
Yeh, K.-H.6
Lu, Y.-S.7
Cheng, A.L.8
Huang, D.C.9
Fritsch, H.10
-
68
-
-
84655164874
-
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
-
[68] Schöffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, Taton M, Fritsch H, Glomb P, and Munzert G (2012). A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 48, 179–186.
-
(2012)
Eur J Cancer
, vol.48
, pp. 179-186
-
-
Schöffski, P.1
Awada, A.2
Dumez, H.3
Gil, T.4
Bartholomeus, S.5
Wolter, P.6
Taton, M.7
Fritsch, H.8
Glomb, P.9
Munzert, G.10
-
69
-
-
84920699404
-
Phase I/II study of volasertib, an intravenous Polo-like kinase inhibitor (Plk), in patients with relapsed/refractory acute myeloid leukemia (AML): Updated phase I results for volasertib monotherapy
-
Abstract S649
-
[69] Döhner H, Bug G, Müller-Tidow C, Krämer A, Lübbert M, Krug U, Schlenk RF, Voss F, Taube T, and Liu D, et al (2014). Phase I/II study of volasertib, an intravenous Polo-like kinase inhibitor (Plk), in patients with relapsed/refractory acute myeloid leukemia (AML): updated phase I results for volasertib monotherapy. Haematologica 99 [Abstract S649].
-
(2014)
Haematologica
, pp. 99
-
-
Döhner, H.1
Bug, G.2
Müller-Tidow, C.3
Krämer, A.4
Lübbert, M.5
Krug, U.6
Schlenk, R.F.7
Voss, F.8
Taube, T.9
Liu, D.10
-
70
-
-
84884926731
-
Cooperative lethality of Polo-like kinases (PLK) and Aurora kinases (AK) in refractory pediatric leukemia
-
Abstract 3573
-
[70] Jayanthan A, Cooper T, Dunn SE, Lewis VA, and Narendran A (2012). Cooperative lethality of Polo-like kinases (PLK) and Aurora kinases (AK) in refractory pediatric leukemia. Blood 120 [Abstract 3573].
-
(2012)
Blood
, pp. 120
-
-
Jayanthan, A.1
Cooper, T.2
Dunn, S.E.3
Lewis, V.A.4
Narendran, A.5
-
71
-
-
84907300532
-
Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy
-
[71] Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, and Ottmann OG, et al (2014). Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood 124, 1426–1433.
-
(2014)
Blood
, vol.124
, pp. 1426-1433
-
-
Döhner, H.1
Lübbert, M.2
Fiedler, W.3
Fouillard, L.4
Haaland, A.5
Brandwein, J.M.6
Lepretre, S.7
Reman, O.8
Turlure, P.9
Ottmann, O.G.10
-
72
-
-
84899409111
-
An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer
-
[72] Stadler WM, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP, Rosen P, Lin CC, Mahoney J, and Modi S, et al (2014). An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer 120, 976–982.
-
(2014)
Cancer
, vol.120
, pp. 976-982
-
-
Stadler, W.M.1
Vaughn, D.J.2
Sonpavde, G.3
Vogelzang, N.J.4
Tagawa, S.T.5
Petrylak, D.P.6
Rosen, P.7
Lin, C.C.8
Mahoney, J.9
Modi, S.10
-
73
-
-
84920657522
-
Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC)
-
Abstract 5504
-
[73] Pujade-Lauraine E, Weber BE, Ray-Coquard I, Vergote I, Selle F, Del Campo JM, Sufliarsky J, Tschope I, Garin Chesa P, and Nazabadioko S, et al (2013). Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC). J Clin Oncol 31 [Abstract 5504].
-
(2013)
J Clin Oncol
, pp. 31
-
-
Pujade-Lauraine, E.1
Weber, B.E.2
Ray-Coquard, I.3
Vergote, I.4
Selle, F.5
Del Campo, J.M.6
Sufliarsky, J.7
Tschope, I.8
Garin Chesa, P.9
Nazabadioko, S.10
-
74
-
-
77954597123
-
Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability
-
[74] Degenhardt Y, Greshock J, Laquerre S, Gilmartin AG, Jing J, Richter M, Zhang X, Bleam M, Halsey W, and Hughes A, et al (2010). Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther 9, 2079–2089.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 2079-2089
-
-
Degenhardt, Y.1
Greshock, J.2
Laquerre, S.3
Gilmartin, A.G.4
Jing, J.5
Richter, M.6
Zhang, X.7
Bleam, M.8
Halsey, W.9
Hughes, A.10
-
75
-
-
84883054675
-
Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation
-
[75] Tandle AT, Kramp T, Kil WJ, Halthore A, Gehlhaus K, Shankavaram U, Tofilon PJ, Caplen NJ, and Camphausen K (2013). Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation. Eur J Cancer 49, 3020–3028.
-
(2013)
Eur J Cancer
, vol.49
, pp. 3020-3028
-
-
Tandle, A.T.1
Kramp, T.2
Kil, W.J.3
Halthore, A.4
Gehlhaus, K.5
Shankavaram, U.6
Tofilon, P.J.7
Caplen, N.J.8
Camphausen, K.9
-
76
-
-
79956014825
-
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies
-
[76] Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt YY, and Allred AJ, et al (2011). Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 17, 3420–3430.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 3420-3430
-
-
Olmos, D.1
Barker, D.2
Sharma, R.3
Brunetto, A.T.4
Yap, T.A.5
Taegtmeyer, A.B.6
Barriuso, J.7
Medani, H.8
Degenhardt, Y.Y.9
Allred, A.J.10
-
77
-
-
84881425734
-
The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents
-
[77] Laufer R, Forrest B, Li SW, Liu Y, Sampson P, Edwards L, Lang Y, Awrey DE, Mao G, and Plotnikova O, et al (2013). The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents. J Med Chem 56, 6069–6087.
-
(2013)
J Med Chem
, vol.56
, pp. 6069-6087
-
-
Laufer, R.1
Forrest, B.2
Li, S.W.3
Liu, Y.4
Sampson, P.5
Edwards, L.6
Lang, Y.7
Awrey, D.E.8
Mao, G.9
Plotnikova, O.10
-
78
-
-
84880709088
-
A phase I dose-escalation study of TKM-080301, a RNAi therapeutic directed against polo-like kinase 1 (PLK1), in patients with advanced solid tumors: Expansion cohort evaluation of biopsy samples for evidence of pharmacodynamic effects of PLK1 inhibition
-
Abstract TPS2621
-
[78] Northfelt DW, Hamburg SI, Borad MJ, Seetharam M, Curtis KK, Lee P, Crowell B, Vocila L, Fredlund P, and Gilbert MJ, et al (2013). A phase I dose-escalation study of TKM-080301, a RNAi therapeutic directed against polo-like kinase 1 (PLK1), in patients with advanced solid tumors: Expansion cohort evaluation of biopsy samples for evidence of pharmacodynamic effects of PLK1 inhibition. J Clin Oncol 31 [Abstract TPS2621].
-
(2013)
J Clin Oncol
, pp. 31
-
-
Northfelt, D.W.1
Hamburg, S.I.2
Borad, M.J.3
Seetharam, M.4
Curtis, K.K.5
Lee, P.6
Crowell, B.7
Vocila, L.8
Fredlund, P.9
Gilbert, M.J.10
-
79
-
-
85019302111
-
KwokR,Ambegia E, and McClintockK,et al(2011). Preclinical characterization of TKM-080301, a lipid nanoparticle formulation of a small interfering RNA directed against polo-like kinase 1
-
[79] Semple SC, Judge AD, Robbins M, Klimuk S, Eisenhardt M, Crosley E, Leung A, KwokR,Ambegia E, and McClintockK,et al(2011). Preclinical characterization of TKM-080301, a lipid nanoparticle formulation of a small interfering RNA directed against polo-like kinase 1. Cancer Res 71, 2829.
-
(2011)
Cancer Res
, pp. 71
-
-
Semple, S.C.1
Judge, A.D.2
Robbins, M.3
Klimuk, S.4
Eisenhardt, M.5
Crosley, E.6
Leung, A.7
-
80
-
-
0242556820
-
The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex
-
[80] Cheng KY, Lowe ED, Sinclair J, Nigg EA, and Johnson LN (2003). The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex. EMBO J 22, 5757–5768.
-
(2003)
EMBO J
, vol.22
, pp. 5757-5768
-
-
Cheng, K.Y.1
Lowe, E.D.2
Sinclair, J.3
Nigg, E.A.4
Johnson, L.N.5
-
81
-
-
77956624673
-
Exploring potential binding modes of small drug-like molecules to the polo-box domain of human polo-like kinase 1
-
[81] Liao C, Park JE, Bang JK, Nicklaus MC, and Lee KS (2010). Exploring potential binding modes of small drug-like molecules to the polo-box domain of human polo-like kinase 1. ACS Med Chem Lett 1, 110–114.
-
(2010)
ACS Med Chem Lett
, vol.1
, pp. 110-114
-
-
Liao, C.1
Park, J.E.2
Bang, J.K.3
Nicklaus, M.C.4
Lee, K.S.5
-
82
-
-
80053229630
-
Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo
-
[82] Yuan J, Sanhaji M, Kramer A, Reindl W, Hofmann M, Kreis NN, Zimmer B, Berg T, and Strebhardt K (2011). Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol 179, 2091–2099.
-
(2011)
Am J Pathol
, vol.179
, pp. 2091-2099
-
-
Yuan, J.1
Sanhaji, M.2
Kramer, A.3
Reindl, W.4
Hofmann, M.5
Kreis, N.N.6
Zimmer, B.7
Berg, T.8
Strebhardt, K.9
-
83
-
-
84885389854
-
Current clinical trials with polo-like kinase 1 inhibitors in solid tumors
-
[83] Yim H (2013). Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs 24, 999–1006.
-
(2013)
Anticancer Drugs
, vol.24
, pp. 999-1006
-
-
Yim, H.1
|